Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of lapatinib in EGFR/HER2-positive advanced chordoma
2009-014456-29Phase 2Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lapatinib in chordoma, sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Overall tumor response rate by Choi criteria extended to MRI. Started Nov 2009; status: completed.
02
Drugs
lapatinib
03
Conditions
chordoma
Beyond the preview
Go deeper on 2009-014456-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014456-29.